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South African Hypertension Guideline 2006  
Joint National Hypertension Guideline Working Group 2006: Y K Seedat1, M A Croasdale2, F J Milne1, L H Opie1, V J Pinkney-
Atkinson1, B L Rayner1, Y Veriava1 
1. Introduction
This is the third hypertension guideline published by the 
Southern African Hypertension Society (SAHS)1-3 and the second 
by the National Department of Health (DOH).4  It is the first 
joint DOH and SAHS hypertension guideline, to ensure that 
treatment in the two sectors is seamless and does not conflict 
on matters of fact or principle.  It represents an important step 
towards the implementation of a national standard of care 
that will translate into quality care for persons living with 
hypertension.  It reflects realistic objectives that can be applied 
widely and aims to diminish the impact of hypertension and 
related cardiovascular disease (CVD) risk in this country. The 
methodology and participants for the 2006 revision are given in 
Annexure A.
   The last two versions of the SAHS guideline have emphasised 
improved diagnosis and treatment, tighter control and risk 
factor stratification.2,3 Other guidelines support the same trends5-9 
as well as the movement to evidence-based guidelines.10,11 The 
SAHS has a policy of ongoing review of its guideline given 
the changing nature of the evidence.  This is highlighted by 
the decision of the British Hypertension Society12 to revise its 
guideline11 in the light of the results of the Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT).13
   The importance of the alliance between the DOH and 
the SAHS is highlighted by past differing definitions of 
hypertension as in the 1998 South Africa Demographic and 
Health Survey14 where hypertension was defined as either 
a blood pressure (BP) of ≥ 160/95 mmHg or the taking of 
antihypertensive medication in persons aged 15 years or older.  
If the internationally accepted definition of hypertension is used 
as in this guideline (BP ≥ 140/90 mmHg), a further 3 million 
people will be added to the hypertensive population.15,16 CVD 
has been shown to be the second highest cause of mortality in 
South Africa, with 4 of the top 20 causes of death accounting for 
7.4% of all deaths.17 All of this has major cost implications for 
CLINICAL GUIDELINE
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Outcomes. Extensive data from many randomised controlled 
trials have shown the benefit of treating hypertension. The 
target blood pressure (BP) for antihypertensive management 
should be systolic BP < 140 mmHg, diastolic BP < 90 mmHg, 
with minimal or no drug side-effects.  However, a lesser 
reduction will elicit benefit although this is not optimal. The 
reduction of BP in the elderly should generally be achieved 
gradually over 6 months.  Stricter BP control is required for 
patients with end-organ damage, co-existing risk factors and 
co-morbidity, e.g. diabetes mellitus.  Co-existent risk factors 
should also be controlled.
Benefits. Reduction in risk of stroke, cardiac failure, renal 
insufficiency and coronary artery disease.  The major 
precautions and contraindications to each antihypertensive 
drug recommended are listed.
Recommendations. Correct BP measurement procedure 
is described.  Evaluation of cardiovascular risk factors 
and recommendations for antihypertensive therapy are 
stipulated.  The total cardiovascular disease risk profile 
should be determined for all patients and this should inform 
management strategies.  Lifestyle modification and patient 
education are cornerstones in the management of every 
patient.  Drug therapy for the patient with uncomplicated 
hypertension should be as follows: first line – low-dose 
thiazide or thiazide-like diuretics; second line – add either an 
angiotensin-converting enzyme inhibitor (ACE-I) or a calcium 
channel blocker (CCB); third line – add another second-line 
drug not already used.  In resistant hypertension where a 
fourth drug is needed, use either a centrally acting drug, 
vasodilator, alpha-blocker, or beta-blocker. The order of drug 
choice may change in those with compelling indications for 
a particular drug class. The guideline includes management 
of specific situations including hypertensive emergency and 
urgency, severe hypertension with target-organ damage and 
hypertension in diabetes mellitus, etc.
Validity. The guideline was developed by a joint Southern 
African Hypertension Society and National Department 
of Health Directorate: Chronic Diseases, Disabilities and 
Geriatrics working group. Input was also obtained from 
representatives of the various related professional societies.
S Afr Med J 2006; 96: 337-362.
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a developing country and requires a national strategy for all 
levels of prevention and management. 
   Hypertension is a global health burden affecting developed 
and developing countries, and South Africa is no exception.18 
The high prevalence of hypertension worldwide has 
contributed to the present and expected pandemic of CVD 
and this is of particular concern in developing countries.19 
The control of hypertension in conjunction with other major 
risk factors such as cigarette smoking, dyslipidaemia and 
diabetes mellitus constitutes the ideal approach to the primary 
prevention of atherosclerotic disease and remains a major 
challenge for the community at large.  The trend towards 
comprehensive cardiovascular risk factor management is now 
the internationally accepted model of care.20
   Hypertension is a costly and major contributor to CVD. In 
1991, CVD accounted for R4 - 5 billion in direct and indirect 
costs.21 This expenditure constituted 7.5% of the direct health 
care spending in South Africa.22 This guideline had adopted 
a more evidence-based approach to the estimation of CVD 
risk which will allow for treatment of those South Africans at 
highest risk and those who can gain maximally from lifestyle 
and drug interventions at the lowest cost, given South Africa’s 
limited national resources.23
2. Objective
The objective of this guideline is to promote evidence-based, 
accessible, and comprehensive management of hypertension 
by health care professionals in the public and private sectors.  
Further, it should act as a resource document for patients 
with hypertension to inform them of the national approach to 
hypertension care in South Africa.
3. Abbreviations
ABPM = ambulatory BP monitoring; ABP = ambulatory BP;
ACE-I = angiotensin-converting enzyme inhibitor;  
ARB = angiotensin II receptor blocker; BP = blood pressure; 
CCB = calcium channel blocker; DBP = diastolic blood 
pressure; SBP = systolic blood pressure.
4. BP measurement
BP measurement is a vital clinical skill but it is poorly 
performed by all health care professional categories.  The 
European Hypertension Society24 and the American Heart 
Association25 published detailed recommendations on the 
measurement of BP which the Joint Hypertension Working 
Group fully endorses.
4.1. Generic measurement principles
These recommendations are generic and apply equally to all 
validated devices, especially clinic and self-measurement of 
BP, e.g. arm position, posture of the patient, cuff size and the 
number of readings that should be taken.  
   BP is recorded using an approved device with the patient 
in a sitting position (with the back supported, arm bared and 
resting on a surface at heart level) for at least 5 minutes before 
measurement.  Patients should not have smoked, ingested 
caffeine-containing beverages or had food in the previous 30 
minutes. In persons aged over 60 years, those with diabetes 
mellitus and others at risk (see Table III), the BP should also 
be recorded after standing for 1 minute to document postural 
hypotension.
   An appropriate size cuff should be used – a standard cuff 
(12 cm) for a normal arm, and a larger cuff (15 cm) for an arm 
with a mid-upper circumference > 33 cm (the bladder within 
the cuff should encircle 80% of the arm).  If an undersized cuff 
is used, the BP can be overestimated (undercuffing), and if the 
cuff and bladder are too large the BP can be underestimated 
(overcuffing).
   Both systolic BP (SBP) and diastolic BP (DBP) should be 
recorded. At the initial consultation BP should be measured 
in both arms, and if there is any discrepancy it should be 
measured thereafter in the arm with the higher BP.  The SBP 
should be first estimated by palpation to avoid missing the 
auscultatory gap.  SBP is measured at the first appearance of 
sound (phase I) and DBP is measured at the disappearance 
of the sounds (phase V). Phase V is also recommended in 
pregnancy.  In cardiac arrhythmias (e.g. atrial fibrillation), the 
highest phase I and lowest phase V are recorded as the SBP 
and DBP, respectively. There are circumstances when both 
phase IV (muffling) and phase V should be recorded, e.g. aortic 
regurgitation, pregnancy, and severe anaemia.
   The BP recorded should be the average of 2 readings taken 
1 minute apart. If the first 2 readings differ by > 5 mmHg, 
additional readings should be taken. Repeat measurements 
should be performed on 3 separate occasions when either 
the initial SBP is between 140 and 160 mmHg or the DBP 
is between 90 and 100 mmHg. This should occur within 2 
months to determine if the patient should be diagnosed as 
hypertensive.  All measurements should preferably be taken at 
the same time of the day and using the same arm.
   The elderly may present special problems with BP 
measurement because there may be considerable BP variability, 
with periods of hypotension as well as hypertension. This 
occurs particularly in hot weather.  The most common form of 
hypertension in the elderly is isolated systolic hypertension, 
due to the stiffening of the large arteries that occurs with 
ageing.
   It may be advisable to check the standing BP in hot weather, 
particularly in diabetics, the elderly, those who have symptoms 
of postural hypotension such as dizziness and those who 
appear dehydrated.26 
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   The BP measurement device and its attachments (tubing, cuff, 
valve) need to be serviced and calibrated at least every 2 years.
4.2 Mercury sphygmomanometer
There are increasing criticisms of the use of mercury 
sphygmomanometers.  Mercury is inert and does not degrade.  
Although it is not toxic to patients or operators when the 
device is intact, mercury becomes a major environmental 
hazard when it is discarded.27 There are international moves to 
replace mercury sphygmomanometers with battery-operated 
digital devices.  However, in South Africa and other developing 
countries, there is concern about the availability of accurate 
devices and the safe disposal of lead-containing batteries, but if 
a mercury sphygmomanometer needs replacement, a validated 
oscillometric device should be considered.  An inexpensive 
device for developing countries is becoming available.28
4.3 Self-measurement of BP
Self-measurement of BP is recommended in selected 
circumstances and for selected target groups:29 (i) suspected 
white-coat hypertension; (ii) to guide antihypertensive 
medication; (iii) the elderly; (iv) pregnant women; (v) those 
with diabetes mellitus; (vi) those with refractory hypertension; 
(vii) to improve adherence to treatment; (viii) to predict 
outcomes; and (ix) to empower the patient.
   The recommendation for the purchase of a device should 
come from the patient’s medical practitioner.  The practitioner 
is responsible for educating the patient on user procedure 
and the types of validated device that are available.  Many of 
the devices currently on the market have not been validated 
according to stringent international standards.  An up-to-date 
list of validated devices can be found on the independent 
websites www.dableducational.com30 or http://afssaps. 
sante.fr.28
   A list of devices can be found on the SAHS website www.
hypertension.org.za or by contacting the SAHS (sahs@
hypertension.org.za).
   Only upper-arm devices are recommended, but even these 
are unsuitable in patients with sustained arrhythmias. They 
should not be used for BP measurement during exercise and 
they are not as specific as ambulatory BP monitoring (ABPM) 
for the diagnosis of white-coat hypertension.
   Ideally, the patient should take 2 early-morning and 2 late-
afternoon readings over 5 days and calculate the average of 
all the readings to establish a reliable reading. Patients must 
discuss any proposed change in drug medication with their 
health care professional.
4.4 Twenty-four-hour ABPM
ABPM is not part of routine BP evaluation but is increasingly 
used worldwide.15 The indications for ABPM are very similar 
to those for self-BP monitoring but are now given in clinical 
terms: (i) when there is a large difference between office BP 
and BP measured elsewhere (pharmacy, self-BP measurement) 
– this is suspected white-coat hypertension and is commonly 
found in the elderly, in diabetics and in pregnancy; (ii) 
refractory hypertension (see section 9) with little clinical target-
organ damage; (iii) when there is clinical target-organ damage, 
but the office BP is normal or borderline, suggesting nocturnal 
hypertension or masked hypertension (not uncommon in 
diabetics); and (iv) suspected postural hypotension (due to 
medication or postprandial).
   The ABPM measuring device must be validated rigorously 
according to acceptable international standards before purchase 
and must, together with its attachments (tubing, cuff, etc.), 
be serviced on a regular basis.  In selected situations where 
ABPM is not available, self-BP monitoring may be used as a 
substitute.5
   An up-to-date list of validated devices can be found on 
independent websites www.dableducational.com30 and http://
afssaps.sante.fr.28 The list can be found on the SAHS website 
www.hypertension.org.za or by contacting the SAHS at sahs@
hypertension.org.za.
4.5 Comparison of different methods of BP 
measurement
Table I shows the comparative value of the three different 
methods of BP measurement. 
Table I. Different methods of BP measurement25
 Clinic Home Ambulatory
Predicts outcome Yes Yes Strongly
Initial diagnosis Yes Yes Yes
Cut-off BP levels (mmHg) 140/90* 135/85 120/70 (mean night)
   135/85 (mean day)
   130/80 (24-hour)*
Evaluation of treatment Yes Yes Limited but valuable
Assess diurnal rhythm No No Yes
*The small difference between the clinic BP and the ambulatory BP (ABP) shown in this table does not clearly reflect that there is an increasing difference between the two 
measurements as the clinic BP rises.  As the clinic BP rises, the ABP rises much less.
31
 Thus a clinic BP of 180/110 mmHg corresponds to an ABP of 150/95 mmHg.  This may result in a 
large difference of 30/15 mmHg between the higher clinic BP levels and the ABP.
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5. Cardiovascular disease risk 
stratification
5.1 Rationale for cardiovascular risk  
assessment
The DOH and the SAHS remain committed to the format of 
the CVD risk assessment as outlined in Tables II and III until 
there is wide national consensus on a different CVD risk model 
by all stakeholders (professionals, providers, government and 
health care funders) and supported by adequate local data.  
This model, developed by the European Hypertension Society 
and the European Society of Cardiology,7 reflects absolute risk 
and the continuous risk associated with BP as used in many 
other guidelines.6,9  It is possible to use the tool as a pragmatic 
risk assessment model which is adaptable for use in multiple 
settings including those low-resource settings where some 
of the measures are unavailable and beyond the resources of 
budgets.32
   Consensus has been reached on the necessity of immediate 
drug treatment for those with known associated clinical 
conditions and/or target-organ damage and/or a  
SBP ≥ 180 mmHg or DBP ≥ 110 mmHg (Fig. 1).23 In the absence 
of associated clinical conditions and/or target-organ damage or 
very high levels of BP, the exact level of BP at which to initiate 
drug treatment has changed over time and remains the subject 
of debate.  
5.2 Risk factors, target-organ damage and associated 
clinical conditions
Table II lists the major risk factors, target-organ damage and 
associated clinical conditions.7 Risk factors that are modifiable 
(e.g. smoking and dyslipidaemia) should be the target of 
lifestyle intervention and other treatment as appropriate. In 
addition to controlling hypertension, target-organ damage and 
associated clinical conditions must be managed appropriately 
and referred if necessary to a higher level of care.
   There is still lack of consensus on the importance of some 
of the newer risk factors such as obesity and the metabolic 
syndrome in treatment decisions.6 For example, obesity may 
be measured using the body mass index (BMI), abdominal 
circumference or waist-to-hip ratio.33 The metabolic syndrome 
has not been listed as a risk factor as in the JNC 7 report6 
despite increasing evidence of its link to cardiovascular risk 
and the future risk of diabetes. The metabolic syndrome 
represents a combination of underlying and major risk 
factors34 but there is debate on which criteria to adopt35-37 and 
on whether the clustering of risk factors represents a greater 
cardiovascular risk over and above the individual components 
as used in the Framingham risk calculation.  However, it 
must be remembered that where the metabolic syndrome is 
present, a SBP ≥ 130 mmHg and/or DBP ≥ 85 mmHg requires 
treatment (weight loss and exercise followed by drugs after an 
appropriate trial of lifestyle modification).
Table II. Major risk factors, target-organ damage and associated clinical conditions*  
Major risk factors Target-organ damage Associated clinical conditions
Levels of systolic and diastolic BP Left ventricular hypertrophy: based on ECG Coronary heart disease
Smoking  Heart failure
Dyslipidaemia  Chronic kidney disease: albumin
   Total cholesterol > 6.5 mmol/l, OR   creatinine ratio > 30 mg/mmol
   LDL > 4 mmol/l, OR   
   HDL men < 1 and women   
   < 1.2 mmol/l   
Diabetes mellitus   
   Men > 55 years   
   Women > 65 years   
Family history of early onset of   
cardiovascular disease  
   Men aged < 55 years  
   Women aged < 65 years
Waist circumference – abdominal obesity
   Men ≥ 102 cm 
   Women ≥ 88 cm
   The exceptions are South Asians 
   and Chinese: men > 90 cm and 
   women > 80 cm.39  
*Based on the European Society of Hypertension/European Society of Cardiology guidelines.7
LDL = low-density lipoprotein; HDL = high-density lipoprotein.
See Table IV 
Microalbuminuria: albumin/creatinine ratio
3 - 30 mg/mmol
Slightly elevated creatinine
  Men 115 - 133 µmol/l
  Women 107 - 124 µmol/l
Stroke or transient ischaemic attack
Peripheral arterial disease 
Advanced retinopathy
   Haemorrhages OR
   Exudates
   Papilloedema
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Table III. Stratification of risk to quantify prognosis* 
 




SBP 120 - 129
or
DBP 80 - 84
High-normal
SBP 130 - 139
or
DBP 85 - 89
Stage 1
Mild hypertension
SBP 140 - 159
or




SBP 160 - 179
or






No other major risk 
factors
Average risk Average risk Low added risk Moderate added risk High added risk
1 - 2 major risk 
factors
Low added risk Low added risk Moderate added risk Moderate added risk Very high added risk




Moderate added risk High added risk High added risk High added risk Very high added risk
Associated clinical 
conditions
High added risk Very high added risk Very high added risk Very high added risk Very high added risk
*Based on the European Society of Hypertension/European Society of Cardiology guidelines.7
Fig. 1. Southern African hypertension management flow diagram based on added cardiovascular disease risk.
Hypertension guideline final draft   2 March 2006 
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Adapted WHO cardiovascular disease-risk management package for low-medium resource settings (23) 
FIGURE 1: SOUTHERN AFRICAN HYPERTENSION MANAGEMENT FLOW DIAGRAM BASED ON ADDED CARDIOVASCULAR DISEASE RISK
STRATIFY ACCORDING TO ADDED RISK (as in risk chart Table III)  





HIGH / VERY HIGH 
ADDED RISK
Monitor BP & other risk factors for 
6 – 12 months 
SBP  140 
or DBP  90 
SBP < 140 
or DBP < 90
SBP < 140 
or DBP < 90
SBP  140 
or DBP  90
Continue to monitor BEGIN DRUG 
TREATMENT
LIFESTYLE MODIFICATION AS APPROPRIATE 
Monitor BP & other risk factors 
for 3 – 6 months 
Ada t  HO cardiovascular disease-risk management package for low-medium settings23
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5.3 Routine baseline investigations
Table IV lists recommended routine basic investigations.  Apart 
from measurements of overweight and obesity, the tests are 
performed annually unless abnormal.  Abnormal or suspicious 
results must be repeated as clinically indicated.
6. Target BP levels
The target BP levels vary according to number of major 
risk factors, target-organ damage and/or associated clinical 
conditions as shown in Table V.  These goals should be added 
to the recommended goals for waist/abdominal circumference, 
blood sugar and lipid levels in patients with the metabolic 
syndrome (see section 8.4).
7. Sustainable hypertension 
management 
The Hypertension Working Group has given considerable 
time, thought and debate to the very real concerns about the 
economic sustainability of lifelong drug therapy.  The issues 
of affordability are considered important factors in both the 
private and public sectors in South Africa.  This becomes even 
more relevant given the proposals for the holistic management 
of hypertension, its complications and disease associations (see 
section 8.4).
   The DOH and SAHS reiterate in the strongest possible 
terms the importance of lifestyle modification at all stages 
of hypertension.  If there are limited resources then drug 
Table IV. Routine investigations 
Investigation Clinic frequency Comments
Body weight/overweight 
   Body weight Every visit 
   Height First visit  < 25 kg/m² for men and women. Use supplied body mass
   Body mass index Every visit  index chart (Annexure B) and define level of obesity38
Abdominal obesity  
   Waist circumference Every visit Use correct method of measurement.
  Goal: Men < 102 cm, women < 88 cm. South Asians and
  Chinese: men < 90 cm, women < 80 cm39
   Waist-to-hip ratio  The waist-to-hip ratio has greater predictive value than body  
  mass index or waist circumference for mycardial infarction  
  but may not be practical in many settings32 
Urine dipstick
   Protein First visit Abnormal dipstick
   Blood Yearly if normal Any one of the following:
   Sugar Repeat at next visit if    Proteinuria ≥ 2+
 abnormal on first visit    Haematuria ≥ 1+
  Refer for immediate further investigation
Microalbuminuria First visit then yearly Performed on diagnosis of type 2 diabetes mellitus or 5 years
   Diabetes mellitus only  after the diagnosis of type 140
Blood tests
   Creatinine Yearly if normal From serum creatinine calculate glomerular filtration rate
   Potassium Yearly if normal
   Glucose  Yearly if normal Consider glucose tolerance test in patients with abnormal
   (fasting preferred)  fasting glucose 5.6 – 7.0 mmol/l
   Random total cholesterol Yearly if normal Measure fasting lipogram if cholesterol > 5.1 mmol/l or in  
  high-risk groups
ECG (resting) Yearly if normal Refer to Southern African Hypertension Society policy brief  
  on left ventricular hypertrophy41
Additional investigations As necessary If secondary causes suspected at first visit or if refractory  
 Referral hypertension exists,  additional investigations should be  
  performed
OR
Table V. Targets for BP-lowering treatment
Stage BP level (mmHg)
All stages < 140/90* 
 *In isolated systolic hypertension 
 do not lower the DBP to < 65 
High-risk patients, for  
example those with:  
   Diabetes mellitus
   Renal disease (macroalbu- 
   minuria and/or elevated 
   creatinine)
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treatment may be delayed in persons with low or moderate 
added cardiovascular risk23 (Table III and Fig. 1).  Recent 
studies emphasise the cost effectiveness of both lifestyle and 
drug management in reducing CVD risk in both developed and 
lesser-developed regions of the world42 and the importance of 
tight BP control in black Americans.43
   In the current environment the price of antihypertensive 
and other drugs fluctuates considerably irrespective of market 
sector.  Where possible, generic equivalents or generic drug 
combinations are encouraged and the cheapest generic in a 
class should be considered provided they are true equivalents. 
The patient should not be changed from one generic to another 
in the same class at frequent intervals solely on the basis of 
lower price. The DOH and the SAHS believe that poorly 
managed hypertension, with the undesirable consequences of 
heart failure, stroke and chronic renal failure, is unacceptable.  
Health professionals, together with patients, must manage 
hypertension, its associated risk factors and target organ 
damage appropriately.  Best practice recommendations should 
be clearly stated and compromises based on limited resources 
must be made deliberately and transparently.
8. Management
The diagnosis of hypertension may be made if repeat BP 
measurements performed on 3 separate occasions when either 
(i) the initial SBP is ≥ 140 mmHg or (ii) the DBP is ≥ 90 mmHg 
taken over a period of 2 months.  If the SBP is ≥ 180 mmHg or 
the DBP is ≥ 110 mmHg then refer to section 9 on severe (stage 
III) hypertension.
   Lifestyle information should be given to every person whose 
BP is measured.  Where the BP is elevated, a programme of 
lifestyle modification should be implemented immediately in 
every case (Fig. 1 and section 8.1).
   These recommendations are further clarified by using  
Table III and Fig. 1 in conjunction.
8.1 Lifestyle modification44,45
A healthy lifestyle remains the cornerstone of the management 
of hypertension for all levels of BP. A healthy lifestyle decreases 
BP, enhances antihypertensive drug efficacy and decreases total 
cardiovascular risk. The DOH’s strategy for a healthy lifestyle 
is supported and includes the following elements that will 
improve BP (Table VI).
   1. Achieve and maintain ideal weight with a BMI between 
18.5 and 24.9 kg/m². For weight loss refer to the two local 
guidelines for the prevention and management of obesity.38,47
   2. Limit total sodium intake to less than 2 400 mg per day by 
consuming less than 1 teaspoon of salt per day. Besides table 
salt, high sodium levels are found in packet soups, stock cubes, 
gravies, processed cheese, many breakfast cereals, bread, salty 
snacks and tinned food. Reduce the intake of those foods, 
remove the salt cellar from the table, and gradually reduce 
added salt in food preparation. Inform patients that food may 
taste bland initially, and encourage the use of lemon juice, 
herbs and spices as alternative seasoning. Taste adaptation to 
reduced sodium intake occurs with time. Food labels list salt 
content as sodium. Sodium-free means less than 5 mg per 100 g 
serving, very low sodium means up to 40 mg per 100 g serving, 
and low sodium means up to 120 mg per 100 g serving. To 
calculate the salt content, multiply sodium content by 2.5.
   3. Limit alcohol intake to 2 standard drinks per day for men 
and 1 standard drink per day for women and small men.  A 
standard drink contains about 10 g of ethanol (e.g. 25 ml 
spirits, 125 ml wine, 340 ml beer, 60 ml sherry, 25 ml liqueur).
   4. Follow the nutrition guidelines reported in the global 
strategy on diet, physical activity and health published by 
the World Health Organization (WHO).44,45 These guidelines 
are incorporated in the various local guidelines.47-49  These 
guidelines emphasise a diet low in total fat with high intake of 
fruit and vegetables (5 portions per day), regular use of low-fat 
dairy products, a high intake of high-fibre wholegrain foods, 
fish rather than red meat, the use of products low in saturated  
fat, low salt, and sparing use of sugar and sugar-containing 
foods. Intake of beverages with high caffeine levels should be 
avoided, but the modest use (1 - 2 cups per day) of coffee will 
not increase BP.
   5. Regular moderate-intensity exercise for at least 30 minutes 
on most or preferably all days of the week. Moderate levels 
of exercise can be achieved by brisk walking and should be 
40 - 60% of peak oxygen consumption (VO2peak). Exercise 
bouts can either be continuous or accumulated in shorter time 
periods throughout the day. The benefit of exercise is dose-
response related, and the early adaptations from a sedentary 
lifestyle to becoming moderately active have the greatest effect. 
Patients with uncontrolled hypertension should embark on 
exercise training only after evaluation and initiation of therapy.
   6. Stop the use of all tobacco products. The use of snuff is 
common among South African women who traditionally do 
not smoke tobacco. Nicotine replacement therapy should be 
used for patients with hypertension while under medical 
supervision.
8.2 Drug therapy
In order to use these recommendations for treatment it 
is essential that the patient’s added cardiovascular risk 
be assessed according to Table III. The level of added 
cardiovascular risk informs the decision to implement drug 
therapy according to the decision flow chart (Fig. 1).  Drug 
treatment should be commenced in the following cases: (i) 
low added risk despite a period of 6 - 12 months of lifestyle 
modification and observation; (ii) moderate added risk 
despite a period of 3 - 6 months of lifestyle modification and 
observation; and (iii) high or very high added risk.
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   There are three important classes of antihypertensive agents 
for the management of persons without compelling indications: 
diuretics (thiazide-like and thiazide), angiotensin-converting 
enzyme inhibitors (ACE-Is) and calcium channel blockers 
(CCBs). Recent studies12,13 have led to a reconsideration of 
the drugs of choice for the management of uncomplicated 
hypertension.  The combination of a thiazide diuretic with a 
beta-blocker should be discouraged especially where there is 
abdominal obesity combined with hypertension as both classes 
of drugs have adverse metabolic consequences and increase the 
risk of new diabetes.50,51
•  Step one: low-dose hydrochlorothiazide (12.5 mg preferred 
up to maximum 25 mg) or thiazide-like diuretic. Higher 
diuretic doses are not recommended because of the risk of 
new diabetes.51
•  Step two and step three: allow for considerations based on 
the cost of the various drug classes and other patient-related 
factors such as the presence of major risk factors, associated 
clinical conditions and target organ damage (Table II).  Where 
there are no other compelling indications, then one of the 
following is recommended as second- or third-line therapy: 
(i) ACE-I (in ACE-I intolerance use angiotensin II receptor 
blockers (ARBs)); and (ii) CCB long-acting dihydropyridines 
or non-dihydropyridines.
   Table VII lists the clinical considerations for the major drug 
groups when selecting antihypertensive drug therapy and 
gives possible contraindications.  The issues relating to drug 
adherence are critical and must be implemented for each 
patient (see section 14). It is crucial to ensure that the patient 
understands the importance of adherence to the treatment 
regimen and brings back drug containers and unused drugs.  
This should be reinforced frequently.  Patient empowerment 
and single daily dose regimens improve compliance.  Where 
appropriate use fixed-dose combinations.  Continued 
monitoring and management of drug side-effects is essential. 
8.2.1 Consensus statement on beta-blockers
Certain beta-blockers (such as atenolol) are no longer 
considered as routine step one through step three treatment 
in view of several major considerations, including the failure 
of atenolol-based therapy in the ASCOT study13 (see under 
Combination Therapy, section 8.3).  Added to this are the meta-
analyses by Carlberg et al.52 and Lindholm et al.53 showing 
that beta-blockade is relatively ineffective in reducing hard 
endpoints, not altering several outcomes and reducing stroke 
only by about half of what was expected by the BP reduction. 
The proposed mechanisms are that: (i) beta-blockers reduce the 
central aortic systolic pressure less than CCBs and ACE-Is, so 
that the pressure conveyed to the cerebral circulation and brain 
Table VI. Lifestyle modification for hypertension care6
Modification Recommendation Approximate SBP reduction
Weight reduction Maintain normal body weight (body mass index*  5 - 20 mmHg/10 kg weight loss
 18.5 - 24.9 kg/m²) by means of limited calorie intake 
 and adequate daily physical activity 
 See Annexure B for body mass index chart
Dietary sodium reduction Reduce dietary sodium intake to ≤ 100 mmol/l 2 - 8 mmHg
 (2.4 g sodium or 6 g sodium chloride (salt) per day)
Restrict alcohol consumption Limit consumption to ≤ 2 standard drinks per day  2 - 4 mmHg
 in men and 1 standard drink a day in women
Limit total fat intake44 Limit total fat intake, reduce saturated and 
 trans-fatty acids
 Recommended maximum fat intake for moderately 
 active adults:
 Female – normal weight = 70 g/day
 Female – overweight = 50 g/day
 Male – normal weight = 95 g/day
 Male – overweight = 70 g/day
OR (preferably)
 total fat intake should be < 30% of total energy 
Increase fruit and vegetable  Increase fruit, vegetables, legumes, whole grains  Will reduce stroke by up to 26%46
consumption and nuts to 5 or more helpings a day  
Limit free sugars Reduce free sugars to less than 40 g/day 
 (8 level teaspoons)
Physical activity44 Engage in regular aerobic physical activity such  4 - 9 mmHg
 as brisk walking at least 30 minutes per day, most 
 days of the week, minimum of 150 minutes/week
Stop using all tobacco products  
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is higher than would be expected from the brachial pressure;54 
and (ii) beta-blockers may precipitate new diabetes,55 especially 
when used with diuretics.50,51
   Also note that contrary to expectations, beta-blockers do not 
reduce cardiovascular mortality or myocardial infarct mortality 
when given for hypertension.56 Regarding the use of those 
beta-blockers not considered in the meta-analysis of Lindholm 
et al.,53 such as carvedilol, bisoprolol and nebivolol, there are no 
cardiovascular outcomes in hypertension.
8.2.2 Consensus statement on the use of ACE-I and ARB
Compared with ACE-Is, ARBs provide more effective 
blockade of the renin-angiotensin system.  The DETAIL study 
in patients with diabetes and microalbuminuria57 and the 
VALIANT study58 in patients post myocardial infarction with 
heart failure or impaired left ventricular dysfunction or both 
are the only major published studies comparing ACE-I with 
ARB on a head-to-head basis.  In both studies there was no 
difference in outcome. The ONTARGET study59 is a major 
Table VII. Indications and contraindications for the major classes of antihypertensive drugs (adapted from the JNC 7 
guidelines6)
  Contraindications
Class Conditions favouring use Compelling Possible
Diuretics  Heart failure Gout Pregnancy
(thiazide;  Elderly hypertensives  Beta-blockers (especially
thiazide-like) Isolated systolic hypertension  atenolol)
 Black hypertensives  
Diuretics Renal insufficiency Not used in other Pregnancy
(loop) Heart failure hypertensives 
Diuretics Heart failure Renal failure
(aldosterone antagonist) Post-myocardial infarction Hyperkalaemia
 Resistant hypertension 
CCB  Elderly patients  Tachyarrhythmias
Long-acting only Isolated systolic hypertension  Heart failure
(dihydropyridine) Angina pectoris  Antiretroviral therapy
 Peripheral vascular disease  
 Carotid atherosclerosis  
 Pregnancy  
 Black hypertensives
CCB non-dihydropyridine Angina pectoris Atrioventricular block Constipation (verapamil)
(verapamil, diltiazem) Carotid atherosclerosis (grade 2 or 3) Antiretroviral therapy
 Supraventricular tachycardia  Heart failure
ACE-Is* Heart failure Pregnancy
 Left ventricular dysfunction Hyperkalaemia
 Post-myocardial infarction Bilateral renal artery
 Non-diabetic nephropathy stenosis
 Type 1 diabetic nephropathy
 Type 2 diabetes mellitus
 Proteinuria   
ARBs* Type 2 diabetic nephropathy Pregnancy
 Type 2 diabetic microalbuminuria Hyperkalaemia
 Proteinuria Bilateral renal artery
 Left ventricular hypertrophy stenosis
 ACE-I cough or intolerance
Beta-blockers Angina pectoris  Asthma Peripheral vascular disease
 Post-myocardial infarction Chronic obstructive Bradycardia
 Heart failure (only some beta-blockers;  pulmonary disease Glucose intolerance
 must up-titrate) Atrioventricular block Metabolic syndrome
 Tachyarrhythmias (grade 2 or 3) Athletes and physically
   active patients
   Non-dihydropyridine  
   CCBs (verapamil, diltiazem)  
   Pregnancy
*There is considerable overlap in outcomes of ACE-Is and ARBs in the management of type 2 diabetes mellitus. Use the most efficactious class of drug according to patient 
circumstances.
General note: In resistant (refractory) hypertension centrally acting agents (selective and non-selective) and α-blockers may be required to control BP (see section 9). 
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study that will further address this issue and is awaited 
with interest. The ARB produced greater regression of left 
ventricular hypertrophy compared with a beta-blocker and 
a 13% reduction in the primary endpoint of cardiovascular 
morbidity and death, and a 25% reduction in stroke.60,61 In 
type 2 diabetes the ACE-Is have prevented the progression 
from normoalbuminuria to microalbuminuria,62 and reduced 
established microalbuminuria.57 ARBs63,64 have also reduced 
microalbuminuria, and delayed the progression of established 
diabetic nephropathy.65,66  ACE-I in combination with 
indapamide,67 or an ARB68 were effective in the secondary 
prevention of stroke.  The price of ARBs remains a negative 
factor until it falls or there is a generic equivalent.  However, 
the overriding importance of drug adherence in BP control 
must be emphasised.
8.2.3 Compelling indications for a specific drug class
Table VIII outlines the compelling indications (high-risk 
conditions) that require certain classes of antihypertensive 
drugs based on randomised controlled trials.  The compelling 
indications for specific classes of drugs apply equally to 
patients from any ethnic group.43 
8.3 Combination therapy
The pathophysiology of hypertension is multifactorial.  Data 
on monotherapy show that the reductions in BP produced 
by monotherapy, i.e. use of a single drug, are often too small 
to achieve recommended or optimal BP levels.  The use of 
combination therapy is recommended for such patients.  
Regardless of which drug classes are combined with each other, 
combination will usually result in an increased BP reduction. 
Combination therapy may be freely selected flexible or fixed 
combinations.  The latter have specific advantages, allowing BP 
control to be achieved with a reduced number of daily tablets 
so that better adherence to therapy is more likely.  Flexible 
dosing of the components allows the dose of one drug to be 
increased while keeping the other constant, thereby facilitating 
a greater awareness by the physician of the constituents of 
the combination, thus reducing the risk of administering 
contraindicated drugs and allowing better identification of 
which drug is responsible for the side-effects that may appear 
during treatment. 
   A rational fixed-dose antihypertensive combination requires 
that each component should be safe and that the combination 
should not elicit additive adverse effects. Each component 
should contribute to the overall effect and the dosages should 
be optimised relative to the predictability of bioavailability 
and the absence of unwanted pharmacokinetic interactions. 
Additionally, the doses chosen should maintain a high peak-
to-trough ratio. The dose-response relationship at the chosen 
combined dose should be close to the maximal effect of the 
two doses, and should not cause excessive hypotension. The 
benefits of combination therapy should include an enhanced 
antihypertensive effect, a better response rate, fewer adverse 
effects, lessened metabolic effects and improved outcomes. 
Effective BP-reducing drug combinations are diuretic and beta-
blocker, diuretic and ACE-I or ARB, CCB with ACE-I, and beta- 
with alpha-blockade.   Black patients respond best to diuretic 
combined with other antihypertensive agents as the majority 
have low plasma renin activities.  Synergism is defined as a 
co-operative action resulting in a total effect that is greater than 
the sum of the individual effects.  Synergism exists with ACE-
Is or ARBs combined with either CCBs or diuretics. Of these 
classes, ACE-Is, ARBs and diuretics have relatively flat dose-
Table VIII. Recommendations on compelling indications for a specific drug class
Any drug that lowers BP unless absolutely contraindicated (Table VII), will confer protection against target-organ damage.  However, 
the following classes of drugs have additional protective properties in the case of the listed associated clinical conditions/target-organ 
damage. 
Compelling indications Drug class 
Angina Beta-blocker OR CCB (rate lowering preferred)69 
Prior myocardial infarct  Beta-blocker AND ACE-I (ARB if ACE-I intolerant).70,71 Verapamil if  
 beta-blockers contraindicated. If heart failure, see below 
Heart failure ACE-I (ARB if ACE-I intolerant) AND certain beta-blockers72,73 
 AND aldosterone antagonist74,75
 For combination ARB and ACE-I see ref.76    
 Loop diuretics for volume overload 
Left ventricular hypertrophy (confirmed by ECG) ARB (preferred)60 OR ACE-I  
Stroke: secondary prevention Low-dose thiazide-like diuretic and 
 ACE-I67 or ARB68
Diabetes type 1 or 2 with or without evidence of  ACE-I OR ARB57,62-66,77,78 – usually in combination with a diuretic
microalbuminuria or proteinuria  
Chronic kidney disease  ACE-I OR ARB – usually in combination with a diuretic 
Isolated systolic hypertension Low-dose thiazide or thiazide-like diuretic OR long-acting CCB79,80
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response BP responses, so that combination with a new drug 
class is more effective in reducing BP than increasing the dose 
of the class initially chosen.
8.3.1 Specific combinations 
Among combination therapies, that of beta-blockade and 
diuretics has been standard practice.  However, data favouring 
this practice are based on old studies when comparisons were 
made versus placebo. The only modern study (the ASCOT 
trial13) comparing this ‘old’ combination, as atenolol plus 
thiazide, with the ‘new’ combination of a CCB (amlodipine) 
plus an ACE-I (perindopril), had to be stopped because of a 
mortality and other major outcome advantages for the ‘new’ 
combination. Regarding other diuretic combinations, that 
with a CCB or an ARB was studied in the VALUE trial.81  The 
CCB-diuretic combination was better in reducing myocardial 
infarction than the ARB-diuretic comparator but gave more 
new diabetes.  A third combination that is much used is that of 
an ACE-I with a diuretic, although there appears to be only one 
outcome study, namely PROGRESS,67 in which the combination 
was more effective than the ACE-I alone in reducing repeat 
stroke.
8.4 Metabolic syndrome
Of increasing prevalence is the metabolic syndrome, the 
criteria for which include obesity, dyslipidaemia and type 2 
diabetes mellitus occurring together with hypertension.  There 
has been considerable debate about the clinical criteria for 
this syndrome34-36 and this guideline recognises that of the 
American Heart Association/National Heart and Lung and 
Blood Institutes as shown in Table IX.37 Thus insulin levels 
or insulin/glucose ratios have no place in the diagnosis. 
The metabolic syndrome is not a clearly defined entity with 
a clear aetiology or underlying mechanism.  Therefore, it 
is recommended that its management should reflect the 
accepted strategies to reduce cardiovascular risk and each of 
the components should be managed if present.  For example, 
increased abdominal girth and BP require initial therapy by a 
combination of intensive diet and exercise.
   Table X reflects the current South African norms for the 
management of dyslipidaemia, obesity and diabetes as 
communicated by the relevant local professional societies.38,82,83 
The Dietary Approaches to Stop Hypertension (DASH) low-
sodium diet will not only lower BP, but will also have a 
favourable effect on weight, lipids and glycaemic control.84 
There is mounting evidence that so-called normal lipid levels 
may be inappropriately high in hypertensive patients and 
certainly are so in patients with hypertensive complications, 
e.g. stroke and myocardial infarction.85,86  Lipid-lowering 
therapy is increasingly part of standard drug therapy in both 
young and old with vascular disease.13,87 In some cases, the use 
of a biguanide, e.g. metformin, may be required in addition 
to exercise to prevent the progression to frank type 2 diabetes 
mellitus in hypertensive patients with central obesity.
   The indications for and cautions against the use of 
aspirin, hormone replacement therapy and antioxidants are 
frequently asked questions. Low-dose aspirin should be 
used for secondary prevention of transient ischaemic attacks, 
Table IX. American Heart Association criteria for clinical diagnosis of the metabolic syndrome37
Any 3 of 5 constitute the diagnosis of the  
metabolic syndrome  Categorical cutpoints
Elevated waist circumference*† Men  > 102 cm, women  > 88 cm
 South Asians and Chinese: Men > 90 cm, women > 80 cm39
Elevated triglycerides  ≥ 1.7 mmol/l
 OR
 On drug treatment for elevated triglycerides
Reduced HDL-C  Men < 1.03 mmol/l, women < 1.29 mmol/l
 OR
 On drug treatment for reduced HDL-C‡
Elevated BP  ≥ 130/≥ 85 mmHg
 OR
 On antihypertensive drug treatment in a patient with a history of hypertension
Elevated fasting glucose  ≥ 6.1 mmol/l
 OR 
 On drug treatment for elevated glucose
*To measure waist circumference, locate top of right iliac crest. Place a measuring tape in a horizontal plane around abdomen at level of iliac crest.  Before reading tape measure, ensure 
that tape is snug but does not compress the skin and is parallel to floor. Measurement is made at the end of a normal expiration.
†Some US adults of non-Asian origin (e.g. white, black, Hispanic) with marginally increased waist circumference (e.g. 94 - 102 cm in men and 80 - 88 cm in women) may have strong 
genetic contribution to insulin resistance and should benefit from changes in lifestyle habits, similar to men with categorical increases in waist circumference. Lower waist circumference 
cutpoint (e.g. ≥ 90 cm in men and ≥ 80 cm in women) appears to be appropriate for Asian Americans, south Asians and Chinese.39
‡Fibrates and nicotinic acid are the most commonly used drugs for elevated triglycerides and reduced HDL-C. Patients taking one of these drugs are presumed to have high 
triglycerides and low HDL-C.
HDL-C = high-density lipoprotein cholesterol.
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stroke and myocardial infarction only once the BP is well 
controlled.  Hormone replacement therapy,88 antioxidants,89 and 
homeopathic and complementary medicines are of no benefit 
in hypertensive patients.
8.5 Holistic management of the complicated patient
The consideration of multiple risk factors leads logically to the 
concept of treating the related co-morbid conditions. A recently 
published European CVD prevention guideline8 outlines a 
more holistic approach.  South Africa requires the development 
of a similar document that takes into consideration the special 
needs of its population. 
   Hypertension can seldom be managed in isolation from other 
related chronic illnesses.  Lifestyle modification, drug therapy 
and the targets of management should be broadened to include 
measures of other risk factors and co-morbidities, e.g. measures 
obesity, blood sugar and lipids as well as BP control (Table IV).  
9. Management of severe hypertension
Patients with severe hypertension (stage 3 DBP ≥ 110 mmHg 
and/or SBP ≥ 180 mmHg) may fall into one of three categories 
which determine the urgency of their treatment.  Patients 
should be managed or referred to the appropriate level of care 
and caregiver in accordance with local protocols.  Sustained 
Table X. Current South African norms for dyslipidaemia, obesity and diabetes
LIPID AND TRIGLYCERIDE GOALS82
  Current recommended South African levels  
  for different levels of risk (adopted by the  
  Society for Endocrinology, Metabolism and 
  Lipid Diabetes of South Africa)
Established coronary artery Total cholesterol < 4.5 mmol/l
disease, diabetes Triglyceride < 1.7 mmol/l
  HDL-C > 1 mmol/l men
  > 1.2 mmol/l women
High cardiovascular disease risk LDL-C* < 2.5 mmol/l
Intermediate Total cholesterol < 5 mmol/l
OR Triglyceride < 1.7 mmol/l
Low cardiovascular disease risk HDL-C > 1 mmol/l men
  > 1.2 mmol/l women
 LDL-C* < 3 mmol/l
*LDL-C is the primary target of treatment.
HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.
OBESITY BODY MASS INDEX38
Classification Body mass index (kg/m²) Risk of chronic, non-communicable diseases
Underweight < 18.5† Low (but risk of other clinical problems may  
  be greater)
Normal weight 18.5 - 24.9 Average
Pre-obese (overweight) 25.0 - 29.9 Increased
Obese class I 30.0 - 34.9 Moderate
Obese class II 35.0 - 39.9 Severe
Obese class III ≥ 40.0 Very severe
†These values are considered to be independent of age and are the same for men and women.
ABDOMINAL OBESITY WAIST CIRCUMFERENCE (cm) 
 Ideal Substantial risk
Men < 94  > 102 
Women < 80  > 88 
DIABETES MELLITUS TYPE 283
Symptoms of diabetes PLUS:
•  Casual plasma glucose concentration ≥ 11.1 mmol/l‡ 
OR
•  Fasting plasma glucose ≥ 7.0 mmol/l§  
OR 
•  2-h plasma glucose ≥ 11.1 mmol/l during an oral glucose tolerance test¶
‡ Casual is defined as any time of day without regard to time since last meal.  The classic symptoms of diabetes include polyuria, polydipsia and unexplained weight loss.
§ Fasting is defined as no caloric intake for at least 8 hours. 
¶ The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water.
Note: In the absence of unequivocal hyperglycaemia with acute metabolic decompensation, these criteria should be confirmed by repeat testing on a different day.  The oral glucose 
tolerance test is not recommended for routine clinical use but as many as 30% of people with diabetes will not be diagnosed if only fasting measurements are done.  Different criteria are 
used to diagnose gestational diabetes in pregnant women. 
OR
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severe hypertension requires immediate drug therapy, and 
lifestyle modification must be followed as soon as possible.
9.1 Asymptomatic severe hypertension
These patients are asymptomatic but have severe hypertension 
with or without evidence of target-organ damage or associated 
clinical conditions.  The patient must be kept in the care setting 
and BP measurement repeated after resting for 1 hour.  If 
the second measurement is still elevated at the same level, 
start oral therapy using 2 drugs together, 1 of which should 
be a low-dose thiazide-like diuretic.  The other is usually a 
dihydropyridine CCB.  Follow up within a week or earlier, 
escalating treatment if needed.  Early referral is advised if BP is 
not controlled within 2 - 4 weeks.
9.2 Hypertensive urgencies and emergencies90
Despite advances in chronic hypertension management, 
hypertensive emergencies and urgencies remain 
serious complications.  Poor compliance with effective 
antihypertensive management, failure of health professionals 
to institute effective antihypertensive therapy, failure to refer 
a patient with resistant hypertension timeously and failure 
to recognise important secondary causes appear to be critical 
factors.  Hypertensive emergencies and urgencies can also be 
seen in hypertension in pregnancy and in the preoperative 
period.  Multiple classes of intravenous antihypertensive drugs 
are available to treat hypertensive emergencies, and specific 
agents may have an advantage in a given clinical situation.  
Orally active agents are used to treat hypertensive urgencies 
and include ACE-Is, CCBs and beta-blockers.  Most patients 
respond well to drug therapy, but problems may arise if BP is 
normalised rapidly.
   While not common, hypertensive emergencies and urgencies 
are likely to be encountered by all clinicians because of the 
high prevalence of chronic hypertension.  It is essential that 
all doctors are familiar with treatment.  There is a paucity of 
information from well-conducted studies on the outcomes of 
various antihypertensive drugs and BP-lowering strategies.  
Therefore, any recommendation is based on case studies, 
clinical reports, comparative studies and expert opinion.
9.2.1 Hypertensive urgency91
This level of hypertension is symptomatic, usually with severe 
headache, shortness of breath and oedema.  There are no 
immediate life-threatening neurological, renal, eye or cardiac 
complications such as are seen in the hypertensive emergencies 
(9.2.2).  Ideally, all patients with hypertensive urgency should 
be treated in hospital.
   Commence treatment with 2 oral agents and aim to lower the 
DBP to 100 mmHg slowly over 48 - 72 hours. This BP lowering 
can be achieved with the use of: (i) long-acting CCBs; (ii) ACE-
I, initially used in very low doses, but avoid if there is severe 
hyponatraemia (serum Na < 130 mmol/l indicates hyper-
reninaemia and BP may fall dramatically with ACE-I); (iii) beta-
blockers; and (iv) diuretics.  Diuretics may potentiate the effects 
of the other classes of drugs when added.  Furosemide should 
be used if there is renal insufficiency or signs of pulmonary 
congestion.
9.2.2 Hypertensive emergency 
A hypertensive emergency exists when acute elevation of 
BP is associated with acute and ongoing organ damage to 
the kidneys, brain, heart, eyes (grade 3 or 4 retinopathy) or 
vascular system.  These patients need rapid (within minutes 
to a few hours) lowering of BP to safe levels.  Once a patient 
is identified as having a genuine hypertensive emergency, 
immediate hospitalisation is essential in an intensive care unit 
with experienced staff and modern facilities.  Intravenous 
antihypertensive therapy, tailored to the specific type of 
emergency, has become the standard of care except for patients 
with stroke (see separate recommendations in box).  The 
potential for harm from overzealous lowering of BP exists 
concurrently with the need for careful and structured BP 
reduction.  
   It should be emphasised that the definition of a hypertensive 
emergency does not explicitly include absolute BP levels, 
although most adult patients with these emergencies 
will have SBP > 220 mmHg and/or DBP >140 mmHg. A 
hypertensive emergency may also be seen at modest BP 
elevations, for example in a previously normotensive woman 
during pregnancy (eclampsia) or in the setting of acute 
glomerulonephritis, especially in children.
   Hypertensive emergencies are uncommon, probably 
occurring in less than 1 - 2% of the hypertensive population, 
but are more common among blacks and older patients.  Most 
patients know that they are hypertensive, and are on treatment. 
Hypertensive emergencies and urgencies may be seen in the 
immediate postoperative period after vascular surgery.
   Hypertensive emergencies are poorly understood in 
terms of initiating factors, but a rapid rise in BP associated 
with increased vascular resistance is suspected as the 
initial derangement.  Smoking, possibly through mediating 
endothelial injury, has long been suspected to be a risk factor 
and smokers have 5 times the risk of developing malignant 
hypertension. Thrombotic (ischaemic) stroke and intracerebral 
haemorrhage should be managed according to the South 
African Stroke Therapy Clinical Guideline (see summary on  
p. 354).92
   Some common clinical hypertensive emergencies are 
described below.
9.2.2.1 Acute cerebrovascular syndromes
Severe hypertension is common in the setting of acute stroke.  
There is debate about whether or not this should be treated, 
and if so, to what immediate goal BP.  Cerebral autoregulation 
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is impaired, and too-rapid lowering of BP may result in 
the extension of an ischaemic stroke.  The American Heart 
Association recommends treating hypertension in the setting 
of intracerebral bleeding when values > 180/105 mmHg, and 
that mean arterial pressure (DBP plus 1/3 pulse pressure) be 
maintained < 130 mmHg. For ischaemic stroke, BP should 
be observed for at least 1 - 2 hours to see if it will decline 
spontaneously. Only a DBP persistently > 120 mmHg or SBP 
> 220 mmHg should be carefully treated with an initial 20% 
reduction in mean arterial pressure.
9.2.2.2 Hypertensive encephalopathy
Hypertensive encephalopathy is a special cerebrovascular 
hypertensive emergency characterised by diffuse cerebral 
dysfunction with headaches, nausea, vomiting and altered 
levels of conscious and rarely with seizures.  Hypertensive 
encephalopathy is frequently accompanied by retinal findings 
of malignant hypertension and acute renal dysfunction.  
Imaging with a computed tomography (CT) scan is usually 
normal or may show diffuse cerebral oedema.  There is 
consensus that the gradual lowering of BP in this situation 
usually leads to a fairly rapid improvement in symptoms. 
Drugs that may be used in this setting include sodium 
nitroprusside and labetalol. The failure of a patient with 
presumed hypertensive encephalopathy to improve within 
6 - 12 hours of BP reduction should prompt an aggressive 
additional evaluation for other causes of the encephalopathic 
process.
9.2.2.3 Acute cardiac syndromes
Severe hypertension in the setting of acute myocardial 
infarction, unstable angina, or pulmonary oedema should be 
treated aggressively along with all the other interventions 
indicated in that setting.  BP treatment reduces the ischaemic 
load on the left ventricle. Intravenous nitroglycerin is an ideal 
agent for this setting because it reduces myocardial oxygen 
consumption and increases blood flow beyond a stenotic area.  
Sodium nitroprusside is a suitable additional drug that can be 
used alone or in combination with nitroglycerin.
9.2.2.4 Postoperative hypertension93
Hypertension is frequent (20 - 75%) in the postoperative state.  
Such severe hypertension tends to occur more in patients 
with poor preoperative BP control, autonomic disorders or a 
history of acute alcohol or cocaine use.  Examples of reversible 
causes of hypertension in the postoperative period include 
pain, hypoxia, a full bladder, hypervolaemia, hypovolaemia, 
persistent vomiting and anxiety.
   The true emergency situation should preferably be treated 
by an appropriate specialist. Admit the patient to an intensive 
care setting for parenteral drug therapy (Table XI) and close 
monitoring.  Do not lower the initial BP by > 25% within  
30 - 120 minutes.  In the next 2 - 6 hours, aim towards  
160/100 mmHg.  This may be achieved by the use of 
intravenous or oral drugs. 
10. Resistant (refractory) hypertension94
Hypertension that remains > 140/90 mmHg despite the use of 
3 antihypertensive drugs in a rational combination at full doses 
and including a diuretic is known as refractory or resistant 
hypertension. The therapeutic plan must have included 
lifestyle measures.  In older patients with isolated systolic 
hypertension, resistant hypertension is diagnosed when triple 
therapy (as above) has failed to control the BP  
< 160/90 mmHg.  Table XII lists some causes of resistant 
hypertension in South Africa that should be considered in 
managing this condition.
   The commonest cause of resistant hypertension in South 
Africa is probably non-adherence (lack of compliance) to 
lifestyle modification and medication, the unavailability of 
medication and other drug-related causes. Once the issues 
relating to lifestyle and adherence to therapy have been 
satisfactorily managed then consideration should be given to 
the addition of the fourth-line drug.  Resistant hypertension 
should, where possible, be managed by specialist physicians.  
Drugs that can be used for fourth-line therapy are listed below 
and users should be conversant with the pharmacology of 
these agents:96 (i) direct vasodilators: hydralazine, minoxidil; 
(ii) centrally acting drugs:  methyldopa, moxonidine; (iii) alpha-
blockers: doxazosin; (iv) beta-blockers: many cardioselective 
agents are available; and (v) aldosterone antagonists.
11. Special considerations for 
hypertension in certain populations
11.1 Blacks and Indians
At comparable BP levels blacks are prone to complications such 
as stroke, heart failure, and renal failure while coronary heart 
Summary management of acute 
stroke92
•  Do not lower BP in acute stroke or use antihypertensive 
medication unless the BP is SBP > 220 mmHg or  
DBP > 120 mmHg, as a rapid fall may aggravate cerebral 
ischaemia and worsen the stroke.  
•  If the BP is above these levels then treatment should aim 
not to lower the BP by more than 15 - 20% in the first 24 
hours.
•  Treatment may be given orally but if the patient is unable 
to swallow then the use of parenteral drugs may be 
warranted.
•  The best parenteral drugs appear to be those that are 
easily titrated and have a minimal effect on cerebral blood 
vessels, e.g. labetalol.  Sodium nitroprusside should be 
administered in an intensive care unit because of its rapid 
onset of action.
hyper guide.indd   354 3/23/06   11:52:05 AM
GUIDELINE
355
April 2006, Vol. 96, No. 4  SAMJ
disease is increasing in frequency.97 The prevalence of diabetes 
mellitus and the metabolic syndrome is higher in Indians 
than in other ethnic groups.98  Compared with whites, blacks 
respond poorly to ACE-I and beta-blockers as monotherapy, 
but this difference disappears once combined with diuretics. 
Overall CCBs show the most consistent response in blacks 
compared with other classes of drugs used as monotherapy.99,100 
11.2 Children and adolescents101
Hypertension in children is an important issue beyond the 
scope of this guideline. Nevertheless measurement of BP 
should be a routine part of paediatric examination, and it 
is essential to use appropriate cuff sizes. Hypertension is 
defined as the SBP and DBP > 95th percentile for age and 
sex (Table XIII) and it is seldom primary in childhood.  A 
detailed investigation should be undertaken for an underlying 
secondary cause. Referral to a specialist for evaluation and 
treatment is essential. 
   In adolescents, hypertension is increasingly linked to obesity.  
The international trend of poor diet and lack of exercise in 
children is leading to an epidemic of obesity with the early 
onset of hypertension and even type 2 diabetes. The early 
recognition of hypertension in these adolescents will be an 
added motivation for both children and parents to institute 
important lifestyle changes.
11.3 Persons living with HIV and AIDS 
Prolonged highly active antiretroviral therapy (HAART) is 
associated with a higher prevalence of systolic hypertension.103 
This suggests that individuals taking HAART may be at 
increased risk of developing hypertension-related conditions 
and underscores the importance of BP monitoring of these 
individuals. When antiretroviral drugs are used, the doses 
of CCBs are variably influenced especially at the start or 
termination or change of therapy. Frequent BP and dose 
checks are advised. Two of the three major classes of 
antiretrovirals, the protease inhibitors and the non-nucleoside 
reverse transcriptase inhibitors, are involved in many drug 
interactions by inhibiting and/or inducing of the key hepatic 
enzyme system, cytochrome P450. CCBs are the major class of 
antihypertensives affected by such drug interactions.104,105
   The first-line antiretroviral regimen is currently based on 
non-nucleoside reverse transcriptase inhibitors (efavirenz or 
nevirapine), which are enzyme inducers, thereby promoting 
the metabolism of all currently available CCBs, through a 
mechanism not well understood,104 and potentially reducing 
their antihypertensive effect. If the first-line regimen fails, 
patients are usually switched to a protease inhibitor regimen 
which decreases the rate of CCB metabolism to increase CCB 
blood levels, with risk of hypotension.  Thus particular care 
must be taken when patients are on first-line antiretroviral 
Table XI. Intravenous and oral drugs for hypertensive emergency 
Drug Dose Indications and precautions Effect on BP
Intravenous
  Nitroglycerin (glyceryl  5 - 10 µg/min Especially useful for myocardial ischaemia BP lowering occurs in
  trinitrate)   2 - 5 minutes
  Dihydralazine 10 mg every 10 - 15 minutes  Avoid in patients with myocardial ischaemia BP lowering occurs
 until either BP is controlled or   in 10 minutes
 a maximum of 50 mg given    
  Sodium nitroprusside 0.25 - 10 µg/kg/min diluted  Admission to intensive care unit BP control is immediate
 in 5% dextrose and adjust  An intra-arterial BP line is desirable 
 dose as necessary  
  Labetalol  2 mg/min to a total dose of  Use where emergency caused by
 1 - 2 mg/kg phaeochromocytoma
  Caution in acute pulmonary oedema 
  Furosemide 40 - 80 mg  Acts only for 6 hours
  Potentiates all of the above drugs 
Oral (use only if IV drugs are not available)
  Nifedipine  Long-acting CCBs must be Preferred in black persons
  Long-acting only  used to prevent rapid and 
 dangerous BP reduction  
 Check dosage according to 
 CCB brand used   
  Captopril  6.25 mg as a test dose Other rapidly acting ACE-I may be BP lowering in 15 - 30
 Increase to 25 mg if BP  used starting with a low test dose minutes
 lowering is not obtained in  DO NOT USE if bilateral renal artery
 15 – 30 minutes stenosis is suspected
  DO NOT USE if pregnancy is suspected
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Table XII. Causes of resistant hypertension in South Africa (adapted from JNC VI)95
Non-adherence to therapy Instructions not understood
 Side-effects 
 Cost of medication and/or cost of attending health care centre
 Lack of consistent and continuous primary care
 Inconvenient and chaotic dosing schedules
 Organic brain syndrome (e.g. memory deficit)
Volume overload Excess salt intake
 Inadequate diuretic therapy 
 Progressive renal damage (nephrosclerosis)





 Ethanol intake of more than 30 g (3 standard drinks) daily
 Anxiety-induced hyperventilation or panic attacks
 Chronic pain
 Intense vasoconstriction (Raynaud’s phenomenon), arteritis
Identifiable causes of hypertension Chronic renal disease
 Renovascular disease




Pseudoresistance ‘White coat hypertension’ or office elevations
 Pseudohypertension in older patients
 Use of regular cuff on very obese arm
Drug-related causes Doses too low 
 Wrong type of diuretic
 Inappropriate combinations
 Rapid inactivation (e.g. hydralazine)
Drug actions and interactions Non-steroidal anti-inflammatory drugs (NSAIDs)
 Sympathomimetics: nasal decongestants, appetite suppressants
 Cocaine and other recreational drugs, caffeine, oral contraceptives
 Adrenal steroids 
 Liquorice (as may be found in chewing tobacco)
 Cyclosporine, tacrolimus, erythropoietin
 Antidepressants (monoamine oxidase inhibitors, tricyclics)
Table XIII.  95th percentile of BP in boys and girls 3 - 16 years of age, according to height101*
 Age             Height percentile for boys                  Height percentile for girls
BP (yrs) 5th 25th 75th 95th 5th 25th 75th 95th
Systolic BP (mmHg)   3 104 107 111 113 104 105 108 110
   6 109 112 115 117 108 110 112 114
 10 114 117 121 123 116 117 120 122
 13 121 124 128 130 121 123 126 128
 16 129 132 136 138 125 127 130 132
Diastolic BP (mmHg)   3 63 64 66 67 65 65 67 68
   6 72 73 75 76 71 72 73 75
 10 77 79 80 82 77 77 79 80
 13 79 81 83 84 80 81 82 84
  16 83 84 86 87 83 83 85 86
* The height percentiles were determined with standard growth curves.  Data are adapted from those of the Task Force on High BP in Children and Adolescents.
102
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therapy and the BP is controlled by CCBs – if the antiretroviral 
therapy should be switched to include a protease inhibitor, 
dramatic falls in BP may result. It is therefore better to avoid 
using CCBs with antiretroviral therapy.104,105
    The metabolism of many beta-blockers may be inhibited by 
protease inhibitors – this is a theoretical interaction of uncertain 
significance. It would be prudent to start with a low dose of a 
beta-blocker in patients on protease inhibitors. 
12. Primordial prevention
Prevention of hypertension depends on adopting strict lifestyle 
measures. The main objective is to avoid or decrease the 
social, economic and cultural determinants that contribute to 
development of hypertension.  Primordial prevention relies 
on health policies that create a congenial environment which 
promotes healthy behaviours and population-wide education 
programmes.  They depend, in turn, on many factors, including 
political commitment, advocacy by health professionals and 
involvement of community leaders and the mass media.106 
Strategies are to prevent the acquisition or enhancement 
of CVD risk factors which include changes in lifestyle and 
diet in blacks brought about by rapid urbanisation. The 
approach should be non-pharmacological, population-based 
and lifestyle-linked. There is a need to develop cost-effective 
methods for the diagnosis and low-cost saving measures for all 
the risk factors of CVD.
13. Prevalence of hypertension
Prevention of hypertension depends on adopting strict 
lifestyle measures. There is evidence that the prevalence of 
hypertension and CVD is increasing rapidly in sub-Saharan 
Africa.106 Two recent surveys indicated that in Tanzania107 
just under 20% of hypertensive subjects were aware of their 
diagnosis, approximately 10% reported receiving treatment 
and less than 1% were controlled (BP < 140/90 mmHg); the 
treatment status for South African black males showed that 
20% were aware of their hypertension, 14% were on treatment 
and only 7% were controlled (BP < 140/90 mmHg) while 
47% of females were aware of their hypertension, 29% were 
on treatment and only 15% were controlled (BP < 140/90 
mmHg).16
14. Patient education
The purpose of patient education is to empower the patient 
to participate in good-quality hypertensive care. People with 
hypertension have a right to information concerning the 
status and progress of their condition. Empowering patients 
to become actively involved in the management of their 
hypertension is the major objective.
   Effective, honest and open two-way communication between 
the care provider and the patient is critically important in the 
management of chronic lifelong conditions. Acquisition of 
communication and counselling skills by health professionals is 
essential, preferably in the vocabulary of the target population. 
The checklist (Annexure C) can be used as a guide for the 
content of hypertension patient education.
   Poor adherence to therapy is the most important cause of 
uncontrolled BP.108-110 Some of the obstacles to adherence are 
shown in Table XIV. 
15. Ongoing management of the patient 
with hypertension
•  Dose titration or stepwise increase should be carried out after 
2 months if the BP remains uncontrolled and adherence is a 
factor.
•  Once a stable target BP has been achieved, follow-up BP 
measurement should be performed every 3 - 6 months.
•  Drug dose should be reduced if the patient presents with 
symptoms of postural hypotension, i.e. dizziness or  
> 20 mmHg fall in SBP on standing.
•  Refer the patient from the primary care level to higher levels 
in the following circumstances: (i) young patients (18 - 30 
years); (ii) pregnancy; (iii) uncontrolled BP despite use of 3 
drugs (resistant hypertension); (iv) any patient with severe 
target-organ damage and/or severe associated clinical 
conditions (most patients with high added risk or very high 
Table XIV. Obstacles to adherence
Treatment characteristics Patient and illness characteristics
Long duration of therapy Asymptomatic nature of the condition leaves people feeling
Complicated regimens that they are not ill
Expensive medications Chronic conditions require constant attention
Side-effects of medications There are no immediate consequences of stopping
Lack of specific appointment times therapy, e.g. one does not feel sick
Long waiting period at clinic or office Social isolation
Lack of consistent and continuous primary care Disrupted home situation
Instructions not understood Psychiatric illnesses
Organic brain syndrome (e.g. memory deficit) 
Medicines not available
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added risk); and (v) hypertensive urgency or emergency.
•  Most patients with low and moderate added risk can be 
managed at primary care level (general practitioner or 
clinic nurse) and can be seen every 6 months.  Patients with 
high and very high added risk with numerous risk factors 
should be managed by physicians or medical subspecialists 
(cardiologists, nephrologists, endocrinologists) and those 
with a special interest in hypertension, and may need 
frequent visits until the BP is controlled.
16. Strategic implications for the 
implementation of this guideline  
This section was developed by the DOH and is endorsed by 
the SAHS.  It is mainly for those who administer health care 
facilities or make policy and has been included as Annexure 
D.  The implementation of the guideline is an active process 
involving more than dissemination and education. It requires 
the full collaboration and co-operation of policy makers, 
administrators and funders. Both the DOH and the SAHS are 
committed to the full implementation of this guideline.
17. Caution 
This national clinical guideline is for reference and educational 
purposes only and is not intended to be a substitute for 
the advice of appropriate health care professionals or for 
independent research and judgement. Neither the DOH nor 
the SAHS accepts responsibility or liability arising from any 
information contained in or any error of omission from the 
protocol or from the use of any information contained in it.
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Annexure A: Methodology
The Southern African Hypertension Society (SAHS) Advisory 
Panel Committee and representatives of the National 
Department of Health (DOH) decided to produce a revised 
joint hypertension guideline in July 2004.  The following 
Joint National Hypertension Guideline Working Group was 
appointed: Prof Y K Seedat (chairperson), Ms M A Croasdale, 
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Prof F J Milne, Prof L H Opie, Dr V J Pinkney-Atkinson, Prof B 
L Rayner, Prof Y Veriava.
   Three meetings of the SAHS Advisory Panel were held 
in June 2004, March 2005 and 1&2 October 2005 in which 
the DOH representatives participated. The Joint National 
Hypertension Guideline Working Group held several meetings.
   The most recent version of the guideline was discussed in 
the light of more recent studies and the South African health 
care environment and was revised into a new draft.  By 
October 2005 a draft guideline with the relevant references was 
presented to the Working Group and SAHS Advisory Panel. 
The purpose of the meetings was to consider the content of the 
draft guideline and either endorse or amend the document. 
The proceedings of the October 2005 were audio recorded and 
transcribed for future reference.
   The final draft document was revised according to the 
proceedings of the consensus meetings and also incorporates 
a further series of comments circulated after the meeting. Two 
versions of the final guideline were circulated widely via the 
SAHS website and by direct e-mails.  
   Comments on the guideline were solicited and included after 
consideration by the Joint National Hypertension Working 
Group.
   The SAHS received no financial support for the development 
of these guidelines.
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   Acknowledgements for input into the process, meetings 
and/drafts of the guideline include:  Prof A Neil (Oxford 
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Study of Obesity, Society for Endocrinology, Metabolism and 
Diabetes of South Africa (SEMDSA)), Prof U V Fritz (Stroke 
Foundation of Southern Africa), and Prof F J Raal (SEMDSA, 
Lipid and Atherosclerosis Society of South Africa). National 
Department of Health representatives: Ms M A Croasdale, Dr 
E Mohamed, Ms N Mdondolo, Mrs C C Kotzenberg. Prof G 
Maartens (Clinical Pharmacology, University of Cape Town), 
for advice on antiretroviral drugs.
   The following SAHS members participated in the guideline 
development process: Prof Y Veriava (President), Dr G Bihl, 
Ms S Gumede, Ms A Maseko, Prof F J Milne, Prof P S Mntla, 
Prof K P Mokhobo, Ms V Mokwena, Dr M T Mpe, Prof D P 
Naidoo, Dr R Nkurunziza, Prof G Norton, Prof L H Opie, Dr 
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Dr P Stead, Prof K Steyn, Dr Y Trinder, Prof A J Woodiwiss.
Annexure C. Therapeutic education for 
patient checklist
•  The major objective is to empower all patients to participate 
actively in management of their non-communicable chronic 
diseases/conditions.
•  Provide information to patients so that they can understand 
hypertension and its consequences if not treated adequately. 
Involve the patient and family or caregiver in the 
management.
•  Inform patients of the distinction between having a risk 
factor and having a disease and the benefits of controlling 
risk factors.
• Reinforce importance of lifestyle modification at each visit. 
•  Inform patients of their BP reading at every visit and 
whether BP is controlled or what the target should be. 
•  Emphasise the importance of adherence to the management 
protocol. 
•  Patients must know the name, strength and dose of the 
drug(s) prescribed, the frequency of doses and the necessity 
of regular ongoing use. 
• Inform patients on how to deal with side-effects. 
•  Patients must be made aware of drug interactions and food/
drug interactions. 
•  Tell patients to take the morning dose on the day of each visit 
to the health service. 
•  Ask patients to return drug containers, even if they are 
empty, at each visit. 
•  Support groups for patients are essential and need to be 
established at all facilities. The focus should be on self-care 
and self-monitoring, emotional needs, cultural differences, 
discrimination, change management and behavioural change.
•  Counsel patients with hypertension who may have 
an excessive fear of strokes or other consequences of 
hypertension. 
•  Educate patients to inform all health care providers they visit 
regarding their hypertension and what drugs they are taking.
• Encourage patients to request BP measurement at each visit.
Annexure D. Strategic implications for 
the implementation of this guideline  
This section was developed by the DOH and is endorsed by 
the SAHS. It is mainly for those who administer health care 
facilities or make policy. The implementation of the guideline 
is an active process involving more than dissemination and 
education. It requires the full collaboration and co-operation 
of policy makers, administrators and funders. Both the DOH 
and SAHS are committed to the full implementation of this 
guideline.
   The key elements of focus to improve the management 
of hypertension and any other non-communicable chronic 
diseases/conditions are: (i) communication; (ii) continuity; (iii) 
co-ordination; (iv) comprehensiveness; (v) community linkages; 
(vi) caring ethos; (vii) care of high quality; (viii) competence; (ix) 
partnerships – working together to deliver best possible care; 
(x) performance – delivering quality care; (xi) professionals 
– the right people delivering service; (xii) patient access – 
delivering fast and convenient care; (xiii) patient empowerment 
– rights and needs are met; and (xiv) prevention – promotion of 
healthy living.
   If the above key elements are considered this will enable 
the creation of innovative care models suitable for developing 
communities that are long-term and will prevent non-
communicable chronic diseases and associated risk factors 
from developing.
•  Control the progression of the non-communicable chronic 
diseases or their risk factors, increase survival and enhance 
quality of life.
•  Allow health professionals, patients and families to share 
complementary knowledge and skills, thus allowing patients 
to become active partners in management of their non-
communicable diseases.
•  Allow for a lifestyle, drug and self-management strategy 
with community and family support.
•  Encourage participation of a broad spectrum of care 
organisations, professionals and informal caregivers.
•  Patient-centred care and service is desired where there is one-
to-one communication and group education.  Inform patients 
on how, where and when to access help and from whom.  
A patient-orientated, tolerant, caring, concerned attitude 
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is required on the part of health care providers.  The latter 
should be sensitive to patients’ socio-economic conditions 
and cultural history.  Empathic communication builds trust 
and is a potent motivator. Implement long-term care models 
where there is a dedicated care provider, dedicated clinic 
time, chronic disease register, etc.
•  A paradigm shift is needed to adjust the health delivery 
system.  To make a tangible difference in non-communicable 
disease morbidity and mortality, a paradigm shift is needed.  
In order to enhance this paradigm shift, a shift from a single 
risk factor approach to a comprehensive risk management 
approach is needed and chronic/long-term care models need 
to be implemented.  Effective chronic/long-term care requires 
a different kind of health care delivery system in which 
there is co-ordinated comprehensive care. There should be a 
move from a ‘find it and fix it’ model to a co-ordinated and 
comprehensive continuum of care, with extended regular 
contact.  The implementation of dedicated services is a clinic 
organisational issue.  It should be implemented at primary 
level for chronic diseases.  Resources and the provision of 
care for patients with non-communicable chronic diseases 
and disabilities should be strengthened and decentralised 
at and to primary level. The chronic long-term care model 
differs from acute care models and the delivery of service 
should reflect this.
•  Institute dedicated hypertension service (team and time) by 
using a team of health professionals specifically assigned 
to deal with patients with hypertension.  As far as possible 
patients should see the same health care provider at each 
visit.  The team members should be appropriately trained 
and carefully selected and not rotated.  Rotation makes 
training one of the major cost drivers in the delivery of 
long-term care.  An overall co-ordinator for chronic care/
long-term care should be selected and be responsible for 
the treatment outcomes in the facility.  All patients with 
hypertension require a dedicated hypertension time, e.g. 
day of week, especially if dedicated hypertension health 
professionals are not available.  Patients should never be 
treated at the same time as patients with acute, curable 
disease unless the latter is the reason for visiting the clinic. 
This will require an effective triage system.  The hallmarks of 
a dedicated hypertension service/care are as follows:
   •  Effective, with the right level of care provided at the right 
time, by the right persons.
   •  Efficient, with appropriate integrated care packages across 
the levels of care.  This will require an effective, well-defined 
referral system, known to patients and health care providers 
and even an appointment system.
   •  Informative, with patients having access to understandable 
information that allows them to make rational decisions 
about care options, treatment, lodging of complaints, etc.
   •  Equitable, so that all patients benefit from service/care that 
is consistent, continuous, available and accessible.
   •  Promotive and preventive aspects must be included in 
the integrated hypertension care package, e.g. therapeutic 
education, life skills training, etc.
•  Adequate equipment must be available to perform the tasks 
and observations as listed in this guideline.
•  Drug therapy. Relevant and appropriate drugs should be 
available at all times and not be changed except by the 
prescriber.  Patients should receive the total amount of drugs 
as prescribed.  Procurement and distribution systems should 
be more effective.
•  National record keeping in the form of chronic disease 
registers should be implemented at all care facilities to 
monitor control and compliance of patients.
•  Patient/health care provider ratio should be reasonable.
•  Patient record/file management should be sequential and 
systematic with each entry dated and signed as appropriate. 
All information should be documented on the record and no 
loose papers or stickers should be allowed.  
•  Self-monitoring equipment should be made available to 
those patients as recommended in the discussion on self-
measurement of BP (see section 4.3).  Each support group 
must have validated self BP measuring devices for group use.
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